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Abstract The transmembrane domains of ErbB receptor
tyrosine kinases are monotopic helical structures proposed to be
capable of direct side-to-side contact with related receptors.
Formation of the resulting homo- or hetero-oligomeric complexes
is considered a key step in ligand-mediated signalling. ErbB-2,
which has not been observed to form active homo-dimers in a
ligand dependent manner, has been implicated as an important
partner for formation of hetero-dimers with other ErbB
receptors. Recent work has shown that the ErbB-2 transmem-
brane domain is capable of forming homo-oligomeric species in
lipid bilayers, while a similar domain from ErbB-1 appears to
have a lesser tendency to such interactions. Here, 2H nuclear
magnetic resonance was used to investigate the role of the ErbB-
2 transmembrane domain in hetero-oligomerisation with that of
ErbB-1. At low total concentrations of peptide in the membrane,
ErbB-2 transmembrane domains were found to decrease the
mobility of corresponding ErbB-1 domains. The results are
consistent with the existence of direct transmembrane domain
involvement in hetero-oligomer formation within the ErbB recep-
tor family. $ 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The ErbB family of receptor tyrosine kinases plays an im-
portant role in regulation of human growth and development.
This family is comprised of four members, and includes the
epidermal growth factor (EGF) receptor (ErbB-1) and the
ErbB-2/neu proto-oncogene. Each is a single polypeptide
chain whose extracellular and cytoplasmic domains are sepa-
rated by a single membrane-spanning hydrophobic segment of
some 22^26 amino acids. Collectively, the ErbB receptors
form a signalling network that regulates cell growth and dif-
ferentiation in response to EGF and other EGF-like ligands
[1,2]. This network is thought to involve both homo-dimeric/
oligomeric and hetero-dimeric/oligomeric receptor associa-
tions, and to be modulated by ligand binding in normal cells
[3]. Such ‘lateral signalling’ appears to widen the range of
biological response by enabling di¡erent signal cascades
from binding of ligands to di¡erent pair-wise combinations
of ErbB receptor molecules. In this regard, it has been sug-
gested that ErbB-2 is the preferred hetero-dimerisation part-
ner of the other ErbB receptors [4^6]. The intensity of signal-
ling from hetero-oligomers has been postulated to be
attributable to increased biological response to these activated
hetero-dimers [7] in addition to an observed decrease in ligand
dissociation from ErbB-2-containing species [8,9]. It has also
been suggested that ErbB-2-containing hetero-oligomers are
the high a⁄nity receptors for ErbB ligands, despite the ab-
sence of an active ErbB-2 homo-dimer [10]. Many human
cancers exhibit high levels of ErbB-2 expression [1,11].
The mechanisms underlying both intrinsic and ligand-in-
duced receptor association are subjects of considerable inter-
est and debate. The transmembrane region is suggested to
provide a major level of control over receptor spatial arrange-
ment, associations and dynamics, which in turn regulate signal
transduction [1,2]. It has been proposed that one aspect of this
control can involve the presence of amino acid motifs which
permit close association of transmembrane segments [12,13].
Thus, Gullick et al. have noted that direct interaction could
occur between adjacent K-helical transmembrane domains via
such association at a non-zero crossing angle [14]. There has
been much discussion as to the basis of the attractive forces
that might be involved [14^16]: workers appear to favour van
der Waals forces, in the context of a knobs-into-holes model
[17,18]. Additionally, recent studies have indicated the poten-
tial importance of hydrogen bonding between side chains or
backbone atoms in stabilising transmembrane domain associ-
ations [19,20]. Such concepts have been reinforced by studies
of glycophorin in detergent micelles [21] and lipid bilayers
[22]. A wide variety of selective mutations have been per-
formed on cultured cell systems to test the role of ErbB trans-
membrane motifs. However, while a signi¢cant number argue
in favour of the associated theories, others do not [13]. Re-
cently, direct measurements have been made on transmem-
brane peptides from ErbB-2/neu, supporting transmembrane
domain involvement in homo-dimeric interactions in dry ¢lms
and in gel phase bilayers [15,23,24]. Our group has described
direct side-to-side homo-oligomer formation by the ErbB-2
transmembrane domain in £uid 1-palmitoyl-2-oleoyl-3-sn-
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phosphatidylcholine (POPC) bilayers, while similar peptides
derived from ErbB-1 remained primarily monomeric [25]. In
the present work, expressed transmembrane peptides from the
class I receptor tyrosine kinases ErbB-2 and ErbB-1 were in-
corporated in £uid membranes and their hetero-oligomeric
interactions studied by 2H nuclear magnetic resonance
(NMR) spectroscopy.
2. Materials and methods
2.1. Materials
POPC was obtained from Avanti Polar Lipids (Birmingham, AL,
USA). Deuterium-depleted water and deuteromethyl L-alanine were
from Cambridge Isotope Laboratories (Andover, MA, USA). 2,2,2-
Tri£uoroethanol, NMR grade, bp 77^80‡C, was from Aldrich (Mil-
waukee, MI, USA). Deuterated peptides were expressed by general
procedures described previously [24,26]. Brie£y, His-tagged peptides
were produced as TrpE fusion proteins, released from TrpE by cya-
nogen bromide cleavage, and puri¢ed using nickel-chelate chromatog-
raphy (Ni-NTA resin, Qiagen). Peptide puri¢cation was monitored by
sodium dodecyl sulphate^polyacrylamide gel electrophoresis (SDS^
PAGE) and con¢rmed by electrospray mass spectrometry.
2.2. Preparation of samples
Liposome preparation for NMR spectroscopy was as described
recently [25]. Brie£y, dry peptide (5^10 mg) and appropriate amounts
of dry POPC were dissolved in 5 ml FACT (formic acid/acetic acid/
chloroform/tri£uoroethanol, 1:1:2:1 ratio by volume) [24] at 25‡C to
produce clear solutions containing various ratios of peptide (or ErbB-
1/ErbB-2 peptide mixtures) to phospholipid. Following complete or-
ganic solvent removal, samples were hydrated with 30 mM HEPES
containing 20 mM NaCl and 5 mM EDTA pH 7.1^7.3, made up in
deuterium-depleted water. The pH of each resulting liposome suspen-
sion was adjusted to 7.0 Q 0.2 and it was this entire sample that was
transferred to an NMR sample tube and used for spectroscopy. Cen-
trifugation of such suspensions at 23‡C and 1500Ug on linear 5^17.5
or 5^30% sucrose density gradients produced single peptide-contain-
ing fractions whose 2H NMR spectra were the same as those of the
unspun suspensions.
2.3. NMR experiments
2H NMR spectra were acquired at 76.7 MHz on a Varian Unity
500 spectrometer using single-tuned Doty 5 and 10 mm static probes
with temperature regulation to Q 0.1‡C. A quadrupolar echo sequence
[27] was employed with full phase cycling and Z/2 pulse width of 4^5
Ws (5 mm probe) or 8^10 Ws (10 mm probe). Pulse spacing was 15^20
Ws and spectral width was 100 kHz. Recycle delay times of 100 and
500 ms were used. Typically, spectra were processed with 150 Hz line
broadening. Spectral simulation was carried out as described previ-
ously [25], using the program WSolids1 (K. Eichele and R.E. Wasy-
lishen, Dalhousie University, Halifax, Canada).
3. Results






Underlined portions indicate the putative transmembrane
domains as predicted using the algorithms developed by
Rost [28]. Bold font indicates sites of deuteromethyl probe
location (side chains of alanine residues). Each sequence con-
tains a putative Sternberg/Gullick motif [12] : SAVVG in the
case of ErbB-2 and TGVVG in ErbB-1. The N-terminal hexa-
His tag does not appear to signi¢cantly a¡ect peptide behav-
iour in membranes, as discussed in previous studies of related
peptides from neu, ErbB-1 and ErbB-2 [24^26].
Fig. 1 presents illustrative 2H NMR spectra as a function of
temperature for ErbB-2TM and ErbB-1TM assembled individ-
ually at 6 mol% in POPC membranes. All measurements were
made on fully hydrated samples maintained well above the
33‡C gel-to-£uid phase transition temperature [29] of this
common natural phospholipid. The spectra contain multiple
components, as anticipated, given that on SDS^polyacryl-
amide gels both transmembrane peptides migrated as mono-
mers in equilibrium with smaller populations of homo-dimers
and oligomers [26]. CD spectra were consistent with the trans-
membrane portions being K-helical in SDS micelles and in
£uid bilayers [24,26] ; and the features within the liposomal
NMR spectra can be understood in this context from an ex-
amination of the following relationship between spectral split-
ting and probe nucleus behaviour.
Elongated amphiphiles dispersed in £uid membranes tend
to undergo rapid symmetric rotation about an axis perpendic-
ular to the plane of the membrane. As a result of this motion,
each 2H nucleus in the molecule gives rise to a ‘Pake’ doublet,
whose splitting (vXQ) re£ects the motional characteristics of
the segment of the molecule to which the 2H nucleus is at-
tached, and its spatial orientation. Eq. 1 describes the quanti-
tative relationship. Peptide^peptide interactions, and asym-
metric or slowed peptide rotational di¡usion, can become
evident as perturbations on this general framework.
vXQ ¼ 3=8ðe2Qq=hÞSmolG3cos23 i31f ð1Þ
e2Qq/h is the nuclear quadrupole coupling constant (165^170
kHz for an aliphatic C-D bond [27,30]) and Smol is the mo-
lecular order parameter (assuming axially symmetric order)
describing orientational £uctuations of the molecule relative
Fig. 1. 2H NMR spectra corresponding to high receptor concentra-
tion. Spectra are displayed for ErbB-2TM and ErbB-1TM at 6 mol%
in £uid, fully hydrated bilayers of POPC. Thick solid arrows indi-
cate the 38.5 kHz splitting arising from peptide rotating I105 s31
(presumed oligomers); hollow arrows indicate narrowed Pake dou-
blets associated with peptides whose rotational di¡usion E105 s31
(presumed monomers). 400 000^600 000 transients were accumulated
in each case.
FEBS 26085 13-5-02
S. Sharpe et al./FEBS Letters 519 (2002) 103^107104
to the bilayer normal. 3i is the orientation of the C-D bond
relative to the molecular rotation axis, the average being over
reorientation of the CD bond with respect to the molecular
symmetry axis. For a deuterated methyl group (three equiv-
alent nuclei) it is convenient to consider 3i to be the angle
between the C-CD3 vector and the molecular long axis, while
introducing an additional factor of 1/3. A given splitting can
be reduced under the conditions of the current experiments by
‘wobble’ of the entire peptide within the membrane and by
¢nite conformational £uctuations of the peptide backbone.
Dominant non-axially symmetric rotation about an axis (e.g.
all two-fold rotational jumps, and three (or higher)-fold jumps
with unequal population weighting of available conformers),
can cause a shift in intensity toward the spectral centre, lead-
ing to signi¢cant obscurement of the Pake splitting; although,
quite commonly, local intensity maxima persist at frequencies
corresponding to those predicted for symmetric motions
about the same axis [31].
For immobilised peptides with little backbone £exibility, in
unoriented liposomes each alanine CD3 group should give rise
to a Pake doublet of splitting approximately 40 kHz (since
rapid symmetric rotation of the methyl group about its
C-CD3 axis persists until temperatures far below 0‡C are
reached. Such a spectrum for deuterated transmembrane pep-
tides in £uid bilayer membranes might be anticipated for pep-
tide oligomers that have formed via lateral association within
the membrane. However Eq. 1 also dictates that peptide axial
rotation and any internal peptide £exibility, leading to a cor-
relation time of 6 1035 s, would in general lead to reduction
of the spectral splitting from 40 kHz to a value determined by
backbone orientation and dynamic behaviour.
In the context of the above arguments, there are two ap-
parent features in each spectrum in Fig. 1. Both peptides show
spectra indicative of a relatively immobile peptide fraction: a
Pake doublet of splittingV38.5 kHz which approaches the 40
kHz value anticipated above. This is much more prevalent in
ErbB-2TM, indicating a greater propensity for side-to-side in-
teractions between peptides. The component decreases in in-
tensity at higher temperatures, indicating a signi¢cant poten-
tial for exchange between mobile and immobile peptide
fractions. Additionally, each spectrum contains motionally
narrowed Pake doublets indicative of peptides undergoing
rapid axial rotation. In the case of ErbB-1TM, three overlap-
ping powder spectra are present, as expected based on past
analysis of these label locations [32]. These narrowed doublets
are interpretable as representing a mobile, probably mono-
meric, fraction undergoing rapid symmetric motions in the
bilayer. The spectral lines comprising these Pake doublets
sharpen appreciably as temperature is increased, consistent
with more rapid peptide axial di¡usion. A third feature is
the narrow peak seen in the centre of each spectrum. We
have described the latter in more detail previously as arising
from peptide in highly curved vesicles and from peptides
whose rotational di¡usion is asymmetric in nature [31] (resid-
ual HOD contributes a partially resolved additional peak 0.2^
0.3 kHz down¢eld from this).
We have noted previously that lowering the peptide concen-
tration in the membrane leads to a signi¢cant reduction of the
immobile fractions, as indicated by a relative decrease in in-
tensity of the spectral component with splitting near 40 kHz
[25]. This is consistent with greater peptide dispersion. In the
case of ErbB-2TM, this decrease is accompanied by the ap-
pearance of intensity in the region of 20^25 kHz (Fig. 2,
left-hand column). While less evident at 1 mol% peptide,
where there is still a signi¢cant presence of immobile oligo-
mers, these new features are clearly seen at 0.25 mol%. This
appears to represent an intermediate state of association for
ErbB-2TM, which we have suggested may re£ect the presence
of a signi¢cant population of homo-dimers and/or small olig-
omers [25]. It is probable that such species would be immobile
at higher peptide concentration and contribute to the spectral
component with splitting near 40 kHz. At higher temperatures
there is a decrease in the components with splittings near 20
kHz and those near 40 kHz; and a corresponding increase in
the mobile, monomeric fraction. The right-hand column in
Fig. 2 shows spectra for ErbB-2TM at 0.25% in the presence
of 0.75 mol% ErbB-1TM (unlabelled). These spectra remain
very similar to those for 0.25% ErbB-2TM alone, indicating
that the aggregation state of this peptide is not changing
due to addition of the ErbB-1 transmembrane domain. In
all cases, spectra of samples containing lower concentrations
of peptide exhibit an increase in the isotropic peak intensity.
This has been observed in past [25] and likely re£ects in-
creased amounts of residual HOD, in addition to increased
populations of peptide undergoing restricted or asymmetric
rotation.
Fig. 2. 2H NMR spectra corresponding to ErbB-2TM at low recep-
tor concentration. Arrayed spectra are displayed for ErbB-2TM at
0.25 and 1 mol% in POPC bilayers (left). Also shown are spectra
for ErbB-2TM in POPC bilayers containing 0.75 mol% unlabelled
ErbB-1TM (right). Thick solid arrows indicate the 38.5 kHz splitting
arising from peptide rotating I105 s31 (presumed oligomers); thin
arrows indicate spectral features attributed to dimers and/or small
oligomers capable of rotation faster than 105 s31 ; hollow arrows
indicate narrowed Pake doublets associated with peptides whose
rotational di¡usion E105 s31 (presumed monomers). Typically
800 000^1000 000 transients were accumulated for each spectrum.
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Fig. 3 demonstrates the result of incorporating unlabelled
ErbB-2TM and deuterated ErbB-1TM together in POPC bi-
layers. The left column shows spectra of this peptide at 1
and 0.5 mol%, which demonstrate a decrease in the small
immobile peptide fraction (the spectral doublet with splitting
near 40 kHz) upon reduction of peptide concentration. There
is, however, little evidence of the third spectral component
with splitting near 20^25 kHz. This would imply that ErbB-
1TM exists primarily as monomers, exhibiting only a weak
tendency for oligomerisation in membranes. By comparison
to the left column in Fig. 2, it would appear that ErbB-2
transmembrane domains exhibit a greater tendency to self
associate in lipid bilayers than ErbB-1.
The right-hand column in Fig. 3 presents spectra of labelled
ErbB-1TM at 0.5 mol% in POPC membranes containing 0.5
mol% unlabelled ErbB-2TM. It is apparent that the fraction of
immobile ErbB-1TM in this case is greater than in the absence
of the ErbB-2 peptide, and is in fact greater than seen at
1 mol% ErbB-1TM. There is evidence of a broadening of the
monomer spectrum, indicative of rapidly reversible side-to-
side associations, and a marked increase in the magnitude
of the immobilised fraction. Also present are features with
splitting near 25 kHz reminiscent of features assigned to in-
termediate motion species in the ErbB-2TM spectrum at 0.25
mol%. Clearly, unlabelled ErbB-2TM is directly in£uencing the
mobility of labelled ErbB-1TM, and the 25 kHz spectral inten-
sity can be interpreted in the context of ErbB-2-directed het-
ero-dimer/oligomer formation.
Simulation of the identi¢able 2H spectral features permitted
quantitation of the coexisting peptide populations, as de-
scribed previously [25]. A summary of oligomer contribution
to total spectral intensity is given in Table 1 for a range of
ErbB-1TM concentrations, in the presence and absence of
ErbB-2TM. It is evident that the greatest ErbB-2TM dependent
oligomerisation of ErbB-1TM occurs at 1 mol% total peptide
concentrations (0.5 mol% each). At 2 mol% total peptide or
higher, the e¡ect is less striking, and increasing the relative
population of ErbB-2TM appears to make little di¡erence.
4. Discussion
We have suggested in the past that, even without invoking
the presence of speci¢c sites that permit close association (e.g.
motifs), transmembrane helical peptides might tend to revers-
ibly associate with one another in bilayer membranes by vir-
tue of behaving as ‘impurities’ in the surrounding liquid^crys-
tal lipid matrix [23,33]. There have been a number of
theoretical analyses of this concept [34^36]. Such association
would not in general be expected to stop at dimer formation,
or necessarily to be of high a⁄nity [18]; although it could
provide one basis for the 40 kHz spectral feature seen in the
present work. However, the ErbB group of receptors are
widely considered to possess sites that may predispose to oli-
gomeric association in response to appropriate extracellular
recognition events [1^3,5,6,12,37].
In the work described here, a fraction of dimers and/or
small oligomers unable to rotate freely in the membrane
may contribute to the observed splitting at V40 kHz. The
observation of distinct smaller spectral splittings associated
with a species rotating at an intermediate rate (the Pake fea-
ture with 20^25 kHz splitting), would seem consistent with the
concept of oligomers having a preferred geometry, as pro-
posed by Gullick et al. for ErbB-2/neu dimers [12,14]. This
phenomenon appears to be somewhat ErbB-2 speci¢c, with
ErbB-1 exhibiting a lower tendency for self association, even
at high peptide concentrations [25]. Here we have observed an
ErbB-2 dependent oligomerisation of the ErbB-1 transmem-
brane domain. It is interesting to note that the phenomenon
of heteroligomer formation seen in this study did not notice-
ably a¡ect spectra of deuterated ErbB-2TM. This implies that
Fig. 3. 2H NMR spectra corresponding to ErbB-1TM at low recep-
tor concentration. Spectra are displayed for ErbB-1TM at 0.5 or
1 mol% in POPC bilayers (left). Spectra in the right-hand column
are of similar samples containing 0.5 mol% labelled ErbB-1TM and
0.5 mol% unlabelled ErbB-2TM. Thick solid arrows indicate the
38.5 kHz splitting arising from peptide rotating I105 s31 (pre-
sumed oligomers); thin arrows indicate spectral features attributed
to dimers and/or small oligomers capable of rotation faster than
105 s31 ; hollow arrows indicate narrowed Pake doublets associated
with peptides whose rotational di¡usion E105 s31 (presumed
monomers). Typically 800 000^1000 000 transients were accumulated
for each spectrum.
Table 1
Relative amounts of oligomeric ErbB-1TM peptide as estimated by
spectral simulation
% oligomer ( Q 5%)
65‡C 35‡C
ErbB-1TM concentration
6 mol% 15 15
2 mol% 17 19
1 mol% 6 5 6 5
0.5 mol% 9 10
ErbB-1TM+ErbB-2TM concentration
1+2 mol% 21 20
1+1 mol% 18 22
0.5+0.5 mol% 21 26
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the ErbB-2 transmembrane domain directs peptide associa-
tions, and is the determinant of oligomer formation. Thus,
our current data appear to support a signi¢cant role for the
transmembrane domain of ErbB-2, potentially mediated by
the proposed dimerisation motif, in the homo- and hetero-
oligomeric association of ErbB receptors. This would be in
keeping with its role as the preferred hetero-dimerisation part-
ner for other members of this family, and points to a possible
mechanism for dimer or oligomer formation in the absence of
an ErbB-2 ligand. ErbB-2TM might then lead to the aggrega-
tion of other peptides, while itself being less in£uenced by
their presence. This e¡ect appears to be less striking at higher
peptide concentrations. We have previously outlined mecha-
nisms by which peptide perturbation of lipid order may in-
hibit formation of speci¢c peptide^peptide associations at very
high concentration [25]. Alternatively, highly immobile ErbB-
2TM may interact less well with other peptides than the mono-
meric or dimeric species present at low concentrations.
The present spectroscopic observations of receptor trans-
membrane domain association were made in the absence of
ligand. It is not known whether oligomeric species of the in-
tact receptors exist within the cell membrane prior to ligand
binding. Previous work by other groups has been unable to
exclude the possibility of populations of exchangeable, inac-
tive oligomers since the assays used typically only permit de-
tection of permanent/long-lived species or activated ligand-
bound forms [4]. Ligand binding could, for instance, stabilise
a particular receptor arrangement leading to a signalling
event. This possibility is in keeping with observations that
there are two populations of ErbB-1 in many cells, one with
a higher a⁄nity for ligand than the other [38]. It has been
suggested that the high a⁄nity binding is to preformed olig-
omers/dimers [6]. In this context, ErbB-2-containing partners
may have even stronger a⁄nity for ligand, through an altered
spatial arrangement or a di¡erent binding site [39]. A recent
study has implicated ErbB-2-containing hetero-dimers as the
high-a⁄nity EGF receptors in vivo [40]. Related work has
suggested that such high a⁄nity receptors may exist as small
oligomers with reduced rates of rotational di¡usion [41].
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